SMO and neoplasm: In a small case report series, 3 patients with NSCLC with Hh pathway activation had been treated with the SMO inhibitor sonidegib with a significant reduction in tumor burden, suggesting that Hh pathway alterations occur in NSCLC and could be an actionable and valuable therapeutic target [19].